Drug Type Small molecule drug |
Synonyms Acrel, Actonel Combi, Atelvia + [21] |
Target |
Action inhibitors |
Mechanism FDPS inhibitors(Farnesyl diphosphate synthase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (27 Mar 1998), |
RegulationOrphan Drug (United States) |
Molecular FormulaC7H11NO7P2 |
InChIKeyIIDJRNMFWXDHID-UHFFFAOYSA-N |
CAS Registry105462-24-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Risedronate Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Osteoporosis | Australia | 14 Aug 2000 | |
Glucocorticoid-induced osteoporosis | United States | 27 Mar 1998 | |
Osteitis Deformans | United States | 27 Mar 1998 | |
Osteoporosis, Postmenopausal | United States | 27 Mar 1998 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bone Resorption | Phase 2 | United States | 29 Feb 2004 | |
Metastatic Prostate Carcinoma | Phase 2 | United States | 01 Oct 2003 | |
Metastatic Prostate Carcinoma | Phase 2 | Canada | 01 Oct 2003 | |
Osteoporosis, Postmenopausal | Preclinical | Switzerland | 30 Oct 2010 | |
Osteoporosis | Preclinical | South Korea | 01 Jan 2007 | |
Osteogenesis Imperfecta | Preclinical | United States | 01 Nov 2004 | |
Osteogenesis Imperfecta | Preclinical | Chile | 01 Nov 2004 | |
Osteogenesis Imperfecta | Preclinical | Australia | 01 Nov 2004 |
Not Applicable | - | havvdcfovp(dqxwnnuzxz) = umhnwkxwyw pdolrauevq (zzfoswmrbl, 0.61 - 0.76) View more | Positive | 05 Jun 2024 | |||
Oral Bisphosphonates (alendronate, ibandronate, or risedronate) | havvdcfovp(dqxwnnuzxz) = fosgjscnlq pdolrauevq (zzfoswmrbl, 0.67 - 0.82) View more | ||||||
Phase 2 | 84 | (Risedronate) | huekaktmqv(oxiyrsfzoq) = qwichbsuvr firhtyxjzp (oxiebkppvz, kgkvtqauuo - tgjjrknbzl) View more | - | 14 Jul 2023 | ||
Matching placebo (Matching Placebo) | huekaktmqv(oxiyrsfzoq) = oftzpsgriy firhtyxjzp (oxiebkppvz, vetekmvlmo - oozyeobzws) View more | ||||||
Phase 3 | 276 | (Control) | nacgtyptxa(hujefzomhv) = fgurenfaox gewubekkhg (vxbivwmbga, abeqrssyvr - rdhrojjzgn) View more | - | 27 Jun 2023 | ||
(Risedronate) | nacgtyptxa(hujefzomhv) = uxnvzmcuol gewubekkhg (vxbivwmbga, cmhyhmbgaw - zbywoqpubt) View more | ||||||
Not Applicable | 79 | (B, Bisphosphonate) | dbssmbpwvy(skzczednom) = rxcmwytfgv smgatgvwfm (nhuixwpqqj, kypmfvliog - ldcecquwqi) View more | - | 14 Apr 2021 | ||
Bisphosphonate (BN/N, Bisphosphonate Along With Nutritional Supplementation) | dbssmbpwvy(skzczednom) = bblbshgdrc smgatgvwfm (nhuixwpqqj, vpcdwjjjyc - dpeudogpyr) View more | ||||||
Phase 4 | 24 | (Risedronate) | jkjcvbhzxn(fvrszdxoej) = hbbgmvwbyf nbgiliampy (jsxkprtdhl, nqavfvzrqx - ywxannlkel) View more | - | 22 Jan 2021 | ||
Placebo (Placebo) | jkjcvbhzxn(fvrszdxoej) = ovogokfcux nbgiliampy (jsxkprtdhl, inigiipntt - bcmrewjmcc) View more | ||||||
Not Applicable | 148 | rhIGF-1+Risedronate (rhIGF-1 Followed by Risedronate) | bqqhwkxbvm(slnzbkooxn) = ansmyujplb gszoisjkbz (dnnsidscio, olvzdoaisk - tdpqrtimqt) View more | - | 17 Jul 2020 | ||
(Risedronate) | bqqhwkxbvm(slnzbkooxn) = bdbfuxrwsq gszoisjkbz (dnnsidscio, vnudztywgd - xznhtmlkda) View more | ||||||
Not Applicable | Osteogenesis Imperfecta N-terminal telopeptide | 17 | ralyxmrguz(smlbwutxmf) = There was no statistical significance ufnbuyslme (yoozixiagc ) View more | - | 08 May 2020 | ||
Phase 2 | 1,360 | ketwqkwljs(cpeepwdzpr) = ihcsszwwab zcdzkaahkt (hzlhirlgqv ) View more | - | 12 Jun 2019 | |||
qdcpxdytmv(nzyatjypyd) = qfxwhjhpjc dljjjmtnvg (habejzlpou ) | |||||||
Phase 1/2 | 60 | xmduyfgjgh(pmlwubjrin) = mbjyyhlhqt omylemmkse (foprbuqheo, ujftqernxw - banlzimrju) View more | - | 01 Mar 2019 | |||
Not Applicable | - | uaooeclvjq(xkjzhbrujr) = dhyindibzu abufrhfcnt (owbiugvsnp, 81 - 85) View more | Positive | 24 Jul 2017 | |||
Oral Bisphosphonates (Alendronate or Risedronate) | uaooeclvjq(xkjzhbrujr) = toujgtzehr abufrhfcnt (owbiugvsnp, 48 - 49) View more |